.

SEC Reports
NASDAQ
Code of Conduct
Audit Committee Charter
Compensation Committee Charter
Nominating Committee Charter


PRESS RELEASES

February 23, 2005
Inkine Reports 2004 Year End Financial Results:
Delivering $0.06 Per Share And Achieving Full Year Profitability

February 22, 2005
Inkine Announces Positive Phase 3 Study Results Of Next Generation Purgative Product - INKP-102

February 17, 2005
Inkine Announces Date Change To February 23rd For Earnings Results And Conference Call

February 17, 2005
Inkine To Present At Bio CEO & Investor Conference

February 16, 2005
Inkine Announces Conference Call For Fourth Quarter And Year End Results

January 31, 2005
Inkine Appoints John M. Cullen, PH.D., J.D. To Senior Vice President And General Counsel

January 18, 2005
Colon Cancer Alliance (CCA) Appoints Inkine CEO, Leonard S. Jacob, M.D., PH.D., To Its Board Of Directors

December 8, 2004
Inkine Completes Enrollment In INKP-102 Phase III Colonoscopy Study And Announces Intent To Return Colirest License

December 6, 2004
Inkine To Present At The First Albany Annual Growth Conference

November 4, 2004
Inkine Announces Third Quarter Results: Strong Revenue Growth And Earnings Coupled With Future Growth Developments

October 25, 2004
Inkine Announces Conference Call For Third Quarter Financial Results

October 21, 2004
Inkine To Present At the Rodman & Renshaw Techvest 6th Annual Healthcare Conference

October 20, 2004
Inkine Announces That A Settlement Has Been Reached In Its Preemptive Rights Class Action Litigation: Settlement Costs And Related Expenses To Be Borne By Third-Party

September 21, 2004
Inkine To Present At The Ubs Global Life Sciences Conference

September 9, 2004
Inkine Initiates Phase III Study Of Advanced Generation Purgative Product  INKP-102

August 24, 2004
Inkine Announces Promotion Of Jeffrey S. Arcara To Vice President Of Commercial Development

August 23, 2004
Inkine Announces Acceptance Of Visicol® Phase IV Constipation Study Results For Publication

August 5, 2004
Inkine Announces Second Quarter Financial Results: Reporting Profitability And Positive Cash Flow

July 29, 2004
Inkine Announces Conference Call For Second Quarter Financial Results

July 26, 2004
Inkine Announces Acceptance Of Final Visicol® Phase IV Constipation Study Results For Presentation At The American College Of Gastroenterology 69th Annual Scientific Meeting

July 15, 2004
Inkine Announces Positive Phase 2 Study Results Of Next Generation Purgative Product  Inkp-102

July 14, 2004
Inkine Announces The Addition Of William Harral III To Its Board Of Directors

Jun 28, 2004
Inkine Pharmaceutical Added To The Russell 2000 Index

June 7, 2004
Inkine Announces Results Of Annual Shareholder s Meeting

May 20, 2004
Inkine Announces The Appointment Of Robyn G. Karlstadt, M.D. To Vice President Of Clinical Operations

May 18, 2004
Inkine CEO to Present at the UBS 2004 Global Specialty Pharmaceutical Conference

May 12, 2004
Inkine completes enrollment in phase 2 study of next generation purgative product  INKP-102

May 10, 2004
Inkine reports first quarter financial results: Product revenue increased by 72% compared to Q1 2003

May 6, 2004
Inkine CEO to be interviewed on CNBC europe and to present at Rodman & Renshaw Techvest Global Healthcare Conference

April 29, 2004
Inkine announces conference call for first quarter financial results

April 19, 2004
Inkine announces positive clinical trial results: Low dose Visicol® is highly effective in treatment of chronic constipation

March 24, 2004
Inkine announces the addition of Del Humphreys to Senior Vice President of sales

March 22, 2004
Inkine begins phase II study of advanced generation purgative product

March 19, 2004
Inkine announces filing of purported class action lawsuit

March 18, 2004
Inkine CEO to appear on CNBC s "Kudlow and Cramer"
Settlement costs and related expenses to be borne by third-party

March 17, 2004
Inkine announces that it is not required to  issue stock to satisfy potential claims for preemptive rights

March 14, 2004
Inkine announces withdrawal of public offering

March 10, 2004
Inkine prices common stock offering

February 25, 2004
Inkine completes enrollment in phase IV study of VISICOL® tablets in patients with constipation

February 20, 2004
Inkine CEO to  open NASDAQ Stock Market to kick of Colorectal Cancer Awareness Month

February 18, 2004
Inkine reports fourth quarter and year end financial results: product revenue increased by 92% compared to previous year

February 04, 2004
Inkine announces conference call for fourth quarter and year end results

January 27, 2004
Inkine licenses VISICOL® to Pharmatel for use in Australia and New Zealand

January 14, 2004
Inkine announces plans to begin phase 2 study of its new generation purgative product

December 10, 2003
Inkine enters into co-promotional agreement with Sigma-Tau for Gastrointestinal Probiotic VSL#3

November 26, 2003
Inkine files registration statement for public offering of common stock

November 25, 2003
Inkine files provisional patent application for a new generation of purgative products

October 30, 2003
Inkine Reports a dramatic swing to profitability: Reporting $1.2 million in net income for its third quarter 2003 financial results

October 28, 2003
Inkine CEO to appear on CNBC's "Morning Call"

October 24, 2003
Inkine announces conference call for third quarter 2003 earnings

October 18, 2003
Inkine announces webcast of its corporate presentation at the Rodman & Renshaw Techvest healthcare conference

October 2, 2003
New England Journal of Medicine article cites Visicol ® as a commonly used medication for constipation

September 25, 2003
Inkine to present at Rodman & Renshaw Techvest healthcare conference

August 5, 2003
Inkine Reports Second Quarter 2003 Financial Results: Income from Operations and Positive Cash Flow

July 29, 2003
Inkine Announces Conference Call for Second Quarter Financial Results

July 22, 2003
Inkine Announces Acceptance of Three Poster Presentations at the American College of Gastroenterology 68th Annual Scientific Meeting

July 18,2003

Inkine Elects Robert F. Apple to its Board of Directors


July 10, 2003
Inkine Eliminates $13 Million in Senior Secured Debt

June 30, 2003
Inkine Initiates Phase IV Constipation Study Using Visicol® Tablets


May 21, 2003
InKine Licenses Visicol® to Paladin Labs Inc. for use in Canada

May 20, 2003
InKine to Present at UBS Warburg Global Specialty Pharmaceuticals Conference

May 12, 2003
InKine to Present at 7th Annual Friedman Billings Ramsey Technology & Growth Investor Conference

May 8, 2003
InKine Granted European Patent for Visicol®

May 6, 2003
InKine Promotes Stephen Skiendzielewski to Vice President of Manufacturing

April 29, 2003
InKine Reports First Quarter 2003 Financial Results: Product Revenues Increase 165% from First Quarter 2002

April 24, 2003
InKine Announces Positive Results of Laxative Study using Visicol!" Tablets

April 23, 2003
InKine Announces U.S. "Notice of Allowance" for Colirest!" Patent

April 22, 2003
InKine Announces Conference Call for First Quarter Financial Results

April 4, 2003
Guidelines Developed by the American Society for Gastrointestinal Endoscopy Cites Visicol!" as a Widely Accepted Bowel Preperation

March 13, 2003
InKine Initiates Dosing of Subjects in Laxative Study of Visicol Tablets

March 12, 2003
InKine Receives Additional Canadian Patent on Colonic Purgative Salts

March 10, 2003
InKine CEO to be Panelist at Specialty Pharmaceutical Investment Conference

February 6, 2003
InKine Reports Fourth Quarter and Year End Financial Results: Strong Demand Fuels Product Revenue Growth

February 3, 2003
InKine Announces Conference Call for Fourth Quarter and Year-End Financial Results

January 8, 2003
InKine Promotes Robert F. Apple to Chief Operating Officer

January 2, 2003
InKine Raises $3.8 Million in Private Placement Financing

December 16, 2002
InKine Announces 13 Million Private Placement of Senior Secured Convertible Notes


Investor Relations Contacts


InKine Pharmaceutical Company, Inc.
1787 Sentry Parkway West
Building 18 Suite 440
Blue Bell, PA  19422
(215) 283-6850 - tel
(215) 283-4602 - fax
[email protected]
www.inkine.com